Intra Cellular Therapies shares owned by Goldman Sachs Group
Quarter-by-quarter ownership of Intra Cellular Therapies (ITCI) shares owned by Goldman Sachs Group
from 13F filings
Historical chart of Goldman Sachs Group investment in Intra Cellular Therapies
Tip: Access up to 7 years of quarterly data
All positions including Intra Cellular Therapies held by Goldman Sachs Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Quarterly reported holdings in Intra Cellular Therapies by Goldman Sachs Group
| Quarter filed | Position value | Share count | Share price at filing |
|---|---|---|---|
| 2025-03-31 | $194M | 1.5M | 131.92 |
| 2024-12-31 | $31M | 376k | 83.52 |
| 2024-09-30 | $33M | 456k | 73.17 |
| 2024-06-30 | $40M | 588k | 68.49 |
| 2024-03-31 | $53M | 766k | 69.20 |
| 2023-12-31 | $41M | 579k | 71.62 |
| 2023-09-30 | $20M | 379k | 52.09 |
| 2023-06-30 | $21M | 335k | 63.32 |
| 2023-03-31 | $25M | 455k | 54.15 |
| 2022-12-31 | $19M | 354k | 52.92 |
| 2022-06-30 | $36M | 629k | 57.08 |
| 2022-03-31 | $29M | 479k | 61.19 |
| 2021-12-31 | $12M | 235k | 52.34 |
| 2021-09-30 | $22M | 587k | 37.27 |
| 2021-03-31 | $28M | 817k | 33.93 |
| 2020-12-31 | $19M | 604k | 31.80 |
| 2020-09-30 | $3.7M | 146k | 25.66 |
| 2020-06-30 | $15M | 586k | 25.67 |
| 2019-12-31 | $7.2M | 211k | 34.31 |
| 2019-09-30 | $858k | 115k | 7.47 |
| 2019-06-30 | $1.8M | 142k | 12.97 |
| 2019-03-31 | $1.3M | 110k | 12.18 |
| 2018-12-31 | $980k | 86k | 11.41 |
| 2018-09-30 | $1.5M | 67k | 21.69 |
| 2018-06-30 | $1.2M | 69k | 17.67 |
| 2018-03-31 | $1.3M | 62k | 21.06 |
| 2017-12-31 | $1.3M | 93k | 14.48 |
| 2017-09-30 | $3.6M | 228k | 15.78 |
| 2017-06-30 | $7.2M | 581k | 12.42 |
| 2017-03-31 | $2.2M | 133k | 16.25 |
| 2016-12-31 | $1.3M | 83k | 15.09 |
| 2016-09-30 | $4.0M | 264k | 15.24 |
| 2016-06-30 | $3.5M | 90k | 38.82 |
| 2016-03-31 | $692k | 25k | 27.82 |
| 2015-12-31 | $1.5M | 27k | 53.79 |
| 2015-09-30 | $1.1M | 27k | 40.03 |
| 2015-06-30 | $1.7M | 52k | 31.95 |
| 2015-03-31 | $349k | 15k | 23.90 |
Top funds holding Intra Cellular Therapies
View all funds holding Intra Cellular Therapies